SYNCORE BIOTECHNOLOGY CO., LTD.
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.syncorebio.com
Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
- Conditions
- Metastatic Pancreas CancerPancreatic AdenocarcinomaLocally Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT03126435
- Locations
- 🇺🇸
Compassionate Cancer Care Medical Group, Inc, Corona, California, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
🇺🇸John B. Amos Cancer Center / IACT Health, Columbus, Georgia, United States
To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer
- Conditions
- Head and Neck Neoplasms
- Interventions
- Drug: SCB01A
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03020823
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Suang Ho Hospital, Taipei, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT03002103
- Locations
- 🇨🇳
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
🇨🇳Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Study of SCB01A in Patient With Head and Neck Cancer
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: SCB01A
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT02488629
- Locations
- 🇨🇳
Keelung Chang Gung Memorial Hospital & lovers lake branch, Keelung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳MacKay Memorial Hospital, Taipei, Taiwan
A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy
- Conditions
- Solid Tumors
- Interventions
- Drug: SCB01A
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT01159522
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- Next